Article Details

Goldman Sachs moves to Not Rated on Fulcrum Therapeutics after study failure - TipRanks

Retrieved on: 2024-09-13 20:15:57

Tags for this article:

Click the tags to see associated articles and topics

Goldman Sachs moves to Not Rated on Fulcrum Therapeutics after study failure - TipRanks. View article details on hiswai:

Excerpt

Goldman Sachs moved to Not Rated on Fulcrum Therapeutics and removed the firm's 12-month price target on the shares, consistent with the practice ...

Article found on: www.tipranks.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up